2020 年年度报告 公司代码：600851 公司简称：海欣股份 900917 海欣 B 股 上海海欣集团股份有限公司 2020 年年度报告 1 / 176 2020 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 众华会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司董事长费敏华、总裁黄源、主管会计工作负责人朱锡峰及会计机构负责人（会计主管人 员）蔡晓斐声明：保证年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 经审计，2020年度公司实现归属于上市公司股东的净利润为119,391,753.57元，加上其他转 入678,238.79元，按照母公司实现的净利润提取10%的法定盈余公积金14,259,674.40元，加上年 初未分配利润449,434,193.70元，扣除应付2019年普通股股利36,211,700.76元，本年度末未分配 利润为519,032, ...

2020 年第三季度报告 公司代码：600851 公司简称：海欣股份 900917 海欣 B 股 上海海欣集团股份有限公司 2020 年第三季度报告 1 / 22 2020 年第三季度报告 目录 | --- | --- | |-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | --- | --- | |---------------|-------| | | | | 重要提示 | | | 公司基本情况. | | | 重要事项 | | | 附录 | | 2 / 22 2020 年第三季度报告 单位：元 币种：人民币 3 / 22 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司董事长费敏华、总裁黄源、主管会计工作负责人朱锡峰及会计机构负责人（会计主管人 员）蔡晓斐保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三 ...

Financial Performance - The company's operating revenue for the first half of 2020 was ¥427,963,157.06, a decrease of 14.93% compared to ¥503,046,378.24 in the same period last year[19] - The net profit attributable to shareholders of the listed company increased by 31.79% to ¥91,912,756.58 from ¥69,739,404.37 year-on-year[19] - The net profit after deducting non-recurring gains and losses surged by 170.67% to ¥73,953,467.56, compared to ¥27,322,181.53 in the previous year[19] - The net cash flow from operating activities was ¥2,870,047.46, a significant recovery from a negative cash flow of ¥29,837,558.44 in the same period last year[19] - The basic earnings per share increased by 31.66% to ¥0.0761 from ¥0.0578 year-on-year[20] - The weighted average return on net assets rose to 2.36%, an increase of 0.4657 percentage points compared to the previous year[20] - The total assets at the end of the reporting period were ¥5,183,396,208.83, a slight increase of 0.48% from ¥5,158,500,594.34 at the end of the previous year[19] - The net assets attributable to shareholders of the listed company decreased by 0.44% to ¥3,831,783,655.56 from ¥3,848,709,791.06 at the end of the previous year[19] - The company reported a total of ¥17,959,289.02 in non-recurring gains and losses during the reporting period[23] - The company achieved operating revenue of 428 million yuan, a decrease of 14.93% compared to the same period last year[32] - The company’s total revenue decreased by 14.93% to CNY 427.96 million, while operating costs fell by 9.03% to CNY 252.76 million[43] - The net profit attributable to shareholders increased by 31.79%, driven by a CNY 32.28 million increase in dividends from Changjiang Securities and a CNY 28.72 million government subsidy[45] Segment Performance - The pharmaceutical segment generated revenue of 305 million yuan, remaining stable year-on-year, while net profit decreased by 22.77 million yuan due to the absence of previous year's gains from the merger of the old factory[33] - The textile segment reported revenue of CNY 96.43 million, a year-on-year decline of 48.5%, with a net loss of CNY 13.39 million, an increase in loss of CNY 11.90 million compared to the previous year[36] - The property leasing business generated revenue of CNY 30.73 million, with a net profit of CNY 10.58 million, an increase of CNY 2.57 million year-on-year[37] - The financial investment segment achieved total income of CNY 66.75 million, representing a year-on-year growth of 87.44%[39] Cash Flow and Liquidity - The net cash flow from operating activities improved to CNY 2.87 million, compared to a negative CNY 29.84 million in the previous year, primarily due to government subsidies of CNY 28.72 million received during the period[43] - The company incurred CNY 10.70 million in employee relocation costs, which negatively impacted net profit by CNY 7.57 million[45] - The company’s cash and cash equivalents at the end of the first half of 2020 were CNY 297,782,587.14, down from CNY 321,542,798.84 at the end of the first half of 2019[107] - The company experienced a significant decrease in cash and cash equivalents, highlighting potential liquidity concerns moving forward[110] Investments and Development - The company is actively developing new products, with the APDC project in Phase III clinical trials, having enrolled 32 cases so far[34] - The company plans to submit a safety update report to the drug regulatory authority within the year, in compliance with new regulations[35] - The company plans to introduce the "Yangtze River Delta G60 Zhejiang Science and Technology Innovation Base (Songjiang)" project, which is expected to positively impact future revenue and net profit[38] - The company is focusing on enhancing its property management team's professionalism and service levels to improve competitiveness in the leasing market[37] Environmental Compliance - The company’s textile and pharmaceutical businesses are subject to strict environmental regulations that may impact operations[53] - The companies have implemented self-monitoring schemes, including automatic and manual monitoring, through qualified third-party organizations[76] - There have been no reported cases of exceeding emission standards across the companies, demonstrating compliance with environmental regulations[71][72][73] Shareholder Information - The top shareholder, Shenzhen Ningrui Investment Management Enterprise, holds 11.73% of shares, totaling 10,170,509 shares[84] - The total number of shares held by the top ten shareholders amounts to 141,528,801 shares, representing a significant portion of the company's equity[84] - The company has no restricted shares among the top ten shareholders, indicating full liquidity of their holdings[85] Corporate Governance - The board of directors has undergone significant changes, with new appointments including Huang Yuan as CEO and Zhu Xifeng as CFO[87] - The company has not reported any changes in controlling shareholders or actual controllers during the reporting period[86] - The company held its annual general meeting on June 18, 2020, where several board members were elected[60] Accounting Policies - The financial statements comply with the requirements of the accounting standards, accurately reflecting the company's financial position and operating results[127] - The company recognizes goodwill when the acquisition cost exceeds the fair value of identifiable net assets acquired[132] - The company applies fair value measurement for financial assets, with changes recognized in other comprehensive income or current profits and losses depending on the classification[147] Risk Factors - The company faced significant market risks due to intense competition in the textile and pharmaceutical sectors, exacerbated by the global impact of COVID-19[52] - The company is currently facing uncertainties in its APDC project, which is in the third phase of clinical trials[54] Profit Distribution - The company has not disclosed any plans for profit distribution or capital reserve transfer to increase share capital during the reporting period[4] - The company reported a profit distribution of -36,211,700.76 CNY to shareholders, indicating a challenging financial period[114]

2020 年第一季度报告 公司代码：600851 公司简称：海欣股份 900917 海欣 B 股 上海海欣集团股份有限公司 2020 年第一季度报告 1 / 24 2020 年第一季度报告 一、 二、 11Í 四、 目录 | --- | |----------------| | | | 重要提示 . | | 公司基本情况 . | | 重要事项 . | | 附录 . | 2 / 24 2020 年第一季度报告 单位：元 币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司董事长费敏华、总裁应政、主管会计工作负责人杨爱民及会计机构负责人（会计主管人 员）蔡晓斐保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | --- | |-------------------------------------- ...

Financial Performance - In 2019, the company achieved a net profit attributable to shareholders of RMB 103,940,134.72, a decrease of 23.15% compared to RMB 135,250,355.63 in 2018[25] - The company's operating income for 2019 was RMB 1,111,742,408.11, reflecting a year-on-year increase of 1.19% from RMB 1,098,675,770.39 in 2018[25] - The net cash flow from operating activities was negative RMB 26,015,409.43, a decline of 146.87% compared to a positive cash flow of RMB 55,503,931.33 in 2018[25] - The net profit after deducting non-recurring gains and losses was RMB 42,660,472.74, down 65.38% from RMB 123,216,108.42 in 2018[25] - Basic earnings per share decreased by 23.13% to ¥0.0861, while diluted earnings per share remained the same[28] - The net profit attributable to shareholders for the first quarter was ¥22,754,351.90, with a total revenue of ¥224,896,589.82[29] - The company achieved a consolidated revenue of 1.112 billion yuan in 2019, representing a growth of 1.2% compared to 2018[43] - The net profit attributable to shareholders was 103.94 million yuan, a decrease of 23.1% from the previous year[43] Dividends and Shareholder Returns - The company plans to distribute a cash dividend of RMB 0.30 per 10 shares, totaling RMB 36,211,700.76, based on a total share capital of 1,207,056,692 shares as of December 31, 2019[6] - The cash dividend for 2019 was set at 0.30 yuan per share, with a total cash distribution of approximately 36.21 million yuan, representing 34.84% of the net profit attributable to shareholders[110] Assets and Liabilities - The net assets attributable to shareholders of the listed company increased to ¥3,848,709,791.06, representing a 12.51% increase compared to the end of 2018[28] - Total assets reached ¥5,158,500,594.34, marking a 14.39% increase from the previous year[28] - The company reported a net cash flow from operating activities of -¥37,280,013.78 for the year[32] - Non-current liabilities due within one year increased by 36.41% to ¥40,564,118.00, primarily due to the transfer of long-term loans from Ganzhou Haixin[81] Revenue Segmentation - The pharmaceutical segment generated revenue of 630 million yuan, up 4.3% year-on-year, while net profit for this segment fell by 14% to 38.88 million yuan[47] - The textile segment reported revenue of 464 million yuan, a decline of 1% from 2018, with a net loss of 4.94 million yuan[48] - The industrial real estate leasing business achieved revenue of 61.87 million yuan, an increase of 13% compared to the previous year[49] - The real estate development sector showed strong performance with Shanghai Haixin Construction Development Co. generating revenue of RMB 132,668,705.06 and a profit increase of 10,731,774.10 RMB[90] Research and Development - The company has increased its R&D investment, focusing on drug consistency evaluation and new drug development[54] - Research and development expenses increased by 26.20% to CNY 19.94 million, indicating a focus on innovation[60] - The company will increase R&D investment by no less than 10% compared to 2019, aiming to enhance future growth potential[101] Market and Strategic Outlook - The company plans to focus on the medical health sector while strategically reducing its textile operations, aiming for a diversified investment structure[97] - The textile industry is expected to face tougher conditions in 2020 due to global economic slowdowns and trade protectionism, despite maintaining a stable export performance in 2019[94] - The overall strategy includes enhancing the financial investment and industrial real estate development while focusing on the medical health industry as the primary growth driver[97] - The company aims to increase revenue from existing assets and strengthen the pharmaceutical sector as a pillar, while controlling costs in the textile sector and stabilizing financial asset returns[101] Corporate Governance and Compliance - The company has not faced any penalties from securities regulatory agencies in the past three years[188] - The company strictly adheres to the requirements of the Company Law, Securities Law, and the Corporate Governance Guidelines, ensuring a sound governance structure and operation[197] - The board of directors consists of 9 members, including 3 independent directors, and operates under established rules to ensure effective decision-making and governance[197] Environmental Compliance - The company’s wastewater discharge from dyeing and printing was 1,100 tons per day, compliant with the standard of 30 mg/l COD[137] - The company has implemented emergency response plans for sudden environmental incidents across its facilities[145] - The company adheres to wastewater discharge standards, with COD concentration ≤ 300 mg/L and ammonia nitrogen (NH3-N) ≤ 25 mg/L[140] Employee and Management Structure - The total number of employees in the parent company is 60, while the total number of employees in major subsidiaries is 1,448, resulting in a combined total of 1,508 employees[191] - The company’s compensation policy is based on internal fairness, incentivization, external competitiveness, legality, and cost control, consisting of fixed and performance-based compensation[193] - The board of directors and supervisors underwent a re-election process, resulting in several changes in positions[188]

Financial Performance - Operating revenue for the period was ¥869,769,473.91, representing an 8.60% increase compared to the same period last year[18]. - Net profit attributable to shareholders of the listed company was ¥95,937,158.49, a decrease of 7.56% year-on-year[18]. - Basic and diluted earnings per share were both ¥0.0795, down 7.56% from the previous year[20]. - Total operating revenue for Q3 2019 reached ¥366,723,095.67, a 17.6% increase from ¥311,870,031.84 in Q3 2018[49]. - Net profit for Q3 2019 was ¥26,703,523.31, a decrease of 11.0% compared to ¥30,360,053.47 in Q3 2018[53]. - The company reported a total profit of ¥35,748,005.07 for Q3 2019, an increase from ¥33,217,567.40 in Q3 2018[53]. - Investment income for Q3 2019 was ¥28,389,019.16, compared to ¥23,753,789.01 in Q3 2018, marking a growth of 19.5%[53]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥5,005,347,060.61, an increase of 11.00% compared to the end of the previous year[18]. - Total liabilities increased to ¥976,333,454.99, up from ¥884,196,087.90, representing an increase of approximately 10.5% year-over-year[41]. - Total current assets decreased to ¥759,089,935.48 from ¥888,945,673.49, indicating a decline of approximately 14.5%[44]. - Long-term equity investments increased to ¥967,804,008.49 from ¥912,098,214.90, indicating growth in investment activities[39]. - Non-current liabilities rose to ¥510,947,534.27 from ¥441,065,025.81, marking an increase of approximately 15.8%[41]. - Current liabilities totaled ¥465,385,920.72, up from ¥443,131,062.09, reflecting an increase of about 5.0%[41]. Cash Flow - Net cash flow from operating activities was -¥103,258,734.16, a significant decline of 515.81% compared to the previous year[18]. - Cash inflow from operating activities for the first three quarters of 2019 was CNY 1,135,957,342.52, an increase from CNY 941,085,022.32 in the same period of 2018[68]. - Cash inflow from investment activities totaled CNY 284,391,902.52, significantly higher than CNY 72,291,799.24 in the same period last year[68]. - Cash outflow from financing activities was CNY 182,270,470.61, compared to CNY 119,034,910.99 in the same period last year[70]. - The ending balance of cash and cash equivalents was CNY 241,888,297.20, down from CNY 333,639,210.36 at the end of the previous year[70]. Shareholder Information - The total number of shareholders at the end of the reporting period was 72,011, with the top ten shareholders holding significant stakes[22]. - The largest shareholder, Shenzhen Ningrui Investment Management Enterprise, held 8.19% of the shares, totaling 98,914,826 shares[22]. Research and Development - Research and development expenses increased by 50.78% to ¥4,160,223.93 from ¥2,759,183.50, reflecting higher R&D investments[27]. - Research and development expenses increased to ¥4,160,223.93 in Q3 2019, up 50.9% from ¥2,759,183.50 in Q3 2018[49]. Comprehensive Income - Other comprehensive income increased by 38.37% to ¥1,251,590,949.02 from ¥904,527,010.40, driven by the rise in stock prices of Changjiang Securities[27]. - Other comprehensive income after tax for Q3 2019 was -¥149,617,012.21, compared to -¥59,021,049.95 in Q3 2018[56]. - Total comprehensive income for Q3 2019 was CNY -122,913,488.90, compared to CNY -28,660,996.48 in Q3 2018[58]. Capital and Investments - The company completed a capital increase for Shanghai Haixin Long Plush Co., Ltd., raising its registered capital to ¥224,170,777.00[30]. - The company established a new textile company in Sihong, Jiangsu, with a 50.93% ownership stake, contributing to market expansion efforts[30]. - Long-term equity investments grew to ¥2,128,140,286.17 from ¥1,956,246,355.24, representing an increase of approximately 8.8%[44]. Accounting Standards - The company implemented new financial accounting standards effective January 1, 2019, including revised standards on financial instruments and leasing[92]. - The adjustments for the initial application of the new financial instrument standards do not retroactively adjust comparative data for prior periods[93].

Financial Performance - The company's operating revenue for the first half of 2019 was CNY 503,046,378.24, an increase of 2.87% compared to CNY 489,015,831.28 in the same period last year[20]. - The net profit attributable to shareholders of the listed company decreased by 11.71% to CNY 69,739,404.37 from CNY 78,988,321.52 year-on-year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses dropped by 66.79% to CNY 27,322,181.53 compared to CNY 82,279,919.36 in the previous year[20]. - The net cash flow from operating activities was negative at CNY -29,837,558.44, a decline of 213.32% from CNY 26,330,531.39 in the same period last year[20]. - Basic earnings per share decreased by 11.62% to CNY 0.0578 from CNY 0.0654 in the same period last year[22]. - The weighted average return on net assets was 1.8943%, down from 2.1978% in the previous year[22]. - The company achieved operating revenue of 503 million RMB, a year-on-year increase of 2.87%[34]. - The net profit attributable to shareholders was 69.74 million RMB, a year-on-year decrease of 11.71%[34]. - The pharmaceutical segment generated operating revenue of 306 million RMB, a year-on-year growth of 3.07%[35]. - The textile segment reported operating revenue of 187 million RMB, a year-on-year decline of 1.76%[36]. Assets and Liabilities - Total assets increased by 16.17% to CNY 5,238,602,930.05 from CNY 4,509,445,358.47 year-on-year[20]. - The net assets attributable to shareholders at the end of the reporting period increased by 15.21% to CNY 3,940,978,880.56 from CNY 3,420,684,395.47 at the end of the previous year[20]. - Other receivables increased by 115.68% to 141.07 million RMB, primarily due to the disposal of old factory receivables[29]. - Fixed assets rose by 66.64% to 368.35 million RMB, mainly due to the transfer of construction in progress to fixed assets[29]. - Total liabilities reached ¥1,085,675,835.53, up from ¥884,196,087.90, representing an increase of about 22.7%[122]. - The company's total assets increased to RMB 5,206,579,298.87 from RMB 4,506,166,552.95, marking a rise of about 15.5%[131]. - Non-current liabilities totaled RMB 415,584,193.22, up from RMB 250,438,093.22, which is an increase of approximately 66.0%[131]. Cash Flow - The net cash flow from operating activities was -29,837,558.44 RMB, a significant decrease compared to 26,330,531.39 RMB in the previous period[149]. - Cash inflow from investment activities totaled 181,211,502.36 RMB, a substantial increase from 20,534,200.34 RMB in the prior period[149]. - The total cash and cash equivalents at the end of the period were 321,542,798.84 RMB, down from 350,206,067.46 RMB in the previous period[151]. - The company experienced a net decrease in cash and cash equivalents of -13,203,104.99 RMB, compared to -148,778,180.14 RMB in the previous period[151]. Investment and R&D - The company increased R&D expenses to 7,920,824.74 yuan, reflecting a growth of 4.13% year-on-year[45]. - The company is advancing the APDC project phase III clinical trials, with 32 cases enrolled by the end of the reporting period[35]. - The company plans to expand its bulk trade business, which is expected to positively impact overall revenue[41]. - The company is focusing on optimizing management and enhancing competitiveness across its business segments amid a challenging economic environment[34]. Market and Competition - The company’s textile and pharmaceutical businesses are facing intense market competition, which may significantly impact performance due to factors like product competitiveness and inventory management[67]. - The company is exposed to market risks, including competition in the textile and pharmaceutical sectors, which could affect performance[67]. - The company is also facing policy risks, such as stricter environmental regulations and changes in pharmaceutical policies, which may impact its operations[68]. Corporate Governance - The company has no major litigation or arbitration matters during the reporting period, indicating a stable legal environment[84]. - The company has not made any changes to its accounting firm or received non-standard audit reports, reflecting compliance with financial regulations[84]. - The company has no significant related party transactions reported during the period, maintaining transparency in operations[86]. - The company’s board approved the 2018 annual report and financial statements during the annual shareholders' meeting held on June 18, 2019[78]. Environmental Compliance - The company has established a wastewater treatment facility with a daily processing capacity of 1,500 tons, ensuring compliance with environmental standards[97]. - The company has implemented online monitoring systems for wastewater treatment, operated by third-party companies[97]. - The company has developed emergency response plans for environmental incidents across its subsidiaries[99]. - The company has not reported any instances of exceeding pollution discharge standards during the reporting period[103]. Shareholder Information - The total number of common shareholders as of the end of the reporting period is 71,095[109]. - The largest shareholder, Shenzhen Ningrui Investment Management Enterprise, holds 93,839,551 shares, accounting for 7.77% of total shares[112]. - The second largest shareholder, Shanghai Songjiang Dongjing Industrial Company, holds 82,082,000 shares, representing 6.80% of total shares[112]. Accounting and Financial Reporting - The financial statements are prepared based on the going concern assumption, adhering to the relevant accounting standards[181]. - The company ensures that the financial statements provide a true and complete reflection of its financial status and operational results[183]. - The company will adjust capital reserves and retained earnings for the difference between the purchase price and the net asset share of the subsidiary when acquiring minority interests[195].

Financial Performance - Net profit attributable to shareholders increased by 24.21% to CNY 22,754,351.90 year-on-year[12] - Operating revenue rose by 7.94% to CNY 224,896,589.82 compared to the same period last year[12] - Basic earnings per share increased by 24.34% to CNY 0.0189 per share[12] - The company's net profit for the first quarter of 2019 was CNY 21,607,879.94, an increase from CNY 15,317,238.31 in the same period of 2018, representing a growth of approximately 41.5%[54] - Operating income for the first quarter of 2019 reached CNY 4,461,759.85, compared to CNY 2,741,149.57 in the first quarter of 2018, indicating a year-over-year increase of about 62.7%[60] - The total profit for the first quarter of 2019 was CNY 23,417,953.07, compared to CNY 16,229,773.89 in the same quarter of 2018, marking an increase of about 44.5%[54] - The company's basic earnings per share for the first quarter of 2019 was CNY 0.0189, up from CNY 0.0152 in the first quarter of 2018, representing a growth of approximately 24.3%[56] - The company reported investment income of CNY 29,655,981.91 in the first quarter of 2019, compared to CNY 27,858,429.52 in the previous year, indicating an increase of about 6.4%[54] Assets and Liabilities - Total assets increased by 13.59% to CNY 5,122,280,207.10 compared to the end of the previous year[12] - The total assets as of March 31, 2019, amounted to CNY 5,119,937,455.87, compared to CNY 4,506,166,552.95 at the end of 2018, representing a growth of 13.6%[50] - The total equity attributable to shareholders increased to CNY 4,674,041,327.99 from CNY 4,207,580,295.15, marking an increase of 11.1%[50] - The total liabilities amounted to CNY 445,896,127.88, an increase from CNY 298,586,257.80, representing a growth of 49.4%[47] - Total current liabilities were CNY 443,131,062.09, remaining unchanged from the previous period[88] - Total non-current liabilities amounted to CNY 441,065,025.81, a decrease of CNY 719,621.37 from the previous period[88] - Total liabilities reached CNY 884,196,087.90, reflecting a decrease of CNY 719,621.37 compared to the last report[88] Cash Flow - Net cash flow from operating activities was negative at CNY -37,280,013.78, compared to CNY -8,065,633.59 in the previous year[12] - Cash inflow from operating activities totaled 245,226,128.80 RMB, down from 268,504,383.82 RMB in the previous year[69] - Total cash inflow from investment activities was 150,344,963.70 RMB, significantly up from 25,174,035.77 RMB in the previous year[72] - Net cash flow from investment activities reached 124,673,530.69 RMB, compared to -210,979,435.00 RMB in the same period last year[72] - Cash inflow from financing activities totaled 19,000,000.00 RMB, down from 49,460,000.00 RMB year-over-year[72] - Net cash flow from financing activities was -932,728.86 RMB, contrasting with a positive 28,706,508.01 RMB in the previous year[72] Shareholder Information - The total number of shareholders reached 36,850, with the top ten shareholders holding significant stakes[16] - The largest shareholder, Shenzhen Ningrui Investment Management, holds 7.77% of the shares[16] Other Financial Metrics - The weighted average return on equity increased by 0.132 percentage points to 0.6230%[12] - The company reported a total of CNY 1,929,718.14 in non-recurring gains and losses for the period[16] - The company has implemented new financial accounting standards since January 1, 2019, affecting the reporting of financial instruments[15] - Research and development expenses increased by 42.48% to ¥3,677,925.37 due to increased R&D investment[23] - Other income surged by 966.67% to ¥640,000.00, mainly due to increased government subsidies from Gannan Haixin[23] - Cash received from investment income rose by 195.51% to ¥9,822,931.82, primarily due to the sale of long-term convertible bonds[26] - Cash received from the disposal of fixed assets increased significantly by 3,806.21% to ¥30,058,103.00, mainly due to an increase in advance payments[26]

Financial Performance - The company achieved a net profit attributable to shareholders of RMB 135,250,355.63, representing a 28.44% increase compared to RMB 105,299,012.35 in 2017[6]. - Operating revenue for 2018 was RMB 1,098,675,770.39, a 9.82% increase from RMB 1,000,436,800.19 in 2017[25]. - The net cash flow from operating activities reached RMB 55,503,931.33, a significant increase of 316.92% compared to RMB 13,312,981.56 in 2017[25]. - The company reported a net profit excluding non-recurring gains and losses of RMB 123,216,108.42, up 27.58% from RMB 96,581,607.15 in 2017[25]. - The net profit attributable to shareholders in Q4 2018 was CNY 31,464,350.63, showing a significant increase compared to previous quarters[28]. - The company reported a significant increase in net cash flow from operating activities, amounting to 55.50 million RMB, up 316.92% year-on-year[55]. - The company achieved a consolidated revenue of 1.10 billion RMB in 2018, representing a year-on-year growth of 9.82%[54]. - The company reported a total revenue of 5,000 million, with a net profit of 1,456.3 million for the reporting period[171]. Dividends and Profit Distribution - The company plans to distribute a cash dividend of RMB 0.35 per 10 shares, totaling RMB 42,246,984.22[6]. - The company distributed a cash dividend of RMB 0.35 per share for the year 2018, totaling RMB 42,246,984.22, which is 31.24% of the net profit attributable to ordinary shareholders[115]. - The cash dividend policy remained unchanged during the reporting period, following the resolutions from the 2017 annual general meeting[112]. - The company did not propose any cash profit distribution plan despite having positive distributable profits for the reporting period[112]. Assets and Liabilities - The net assets attributable to shareholders decreased by 9.55% to CNY 3,420,684,395.47 from CNY 3,781,691,536.26[27]. - Total assets decreased by 7.82% to CNY 4,509,445,358.47 from CNY 4,892,139,818.15[27]. - Cash and cash equivalents decreased by 32.82% to CNY 335,455,903.83, representing 7.44% of total assets[37]. - The company's cash and cash equivalents decreased by 32.82% compared to the beginning of the year, primarily due to investments in the Anji Tongguang project (85 million RMB) and the purchase of convertible bonds from Changjiang Securities (100 million RMB)[40]. - Short-term borrowings increased by 34.33% compared to the beginning of the year, primarily due to new bank loans from Xi'an Haixin and other enterprises[40]. - The company’s non-current liabilities due within one year increased by 50.94%, primarily due to the transfer of long-term borrowings from Gannan Haixin to the repayment period[40]. Segment Performance - The textile segment achieved revenue of 468 million RMB, a 13.59% increase from 412 million RMB, while the medical segment reported revenue of 604 million RMB, a 6.6% increase[46][48]. - The company’s net profit from the medical segment saw a significant increase of 454%, reaching 45.20 million RMB, driven by a 79.9% increase in revenue from Gannan Haixin[48]. - The textile industry reported a gross margin of 18.50%, while the pharmaceutical manufacturing segment had a gross margin of 79.32%[62]. Research and Development - Research and development expenses rose to 15.80 million RMB, reflecting an 18.63% increase compared to the previous year[55]. - The company reported a total R&D investment of 23,658,681.31 CNY, which represents 2.15% of total revenue[73]. - The company is committed to research and development, focusing on new product innovations to meet market demands[172]. Risk Management and Compliance - The company has outlined potential risks in its future development strategy and operational plans[8]. - The company recognizes the risks associated with market competition in its textile and pharmaceutical businesses, which could significantly impact performance[104]. - The company is aware of potential policy risks, including stricter environmental regulations and real estate market controls, which may affect its operations[105]. - The company emphasizes the importance of internal controls and risk management to enhance operational efficiency and mitigate risks[102]. Environmental Compliance - Nanjing Haixin Lining's wastewater discharge concentration for COD is 176 mg/L, which is below the standard of 200 mg/L[136]. - Baoding Haixin's wastewater discharge total is 1,100 tons/day, meeting the COD standard of 200 mg/L[136]. - The company has implemented third-party monitoring for wastewater treatment to ensure compliance with environmental standards[143]. - The company has established emergency response plans for environmental incidents across its facilities[142]. Corporate Governance - The company has a strong governance structure with independent directors and a diverse management team, ensuring effective oversight and decision-making[173]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with legal requirements[193]. - The company has established a performance evaluation and incentive mechanism for senior management, linking compensation to company and individual performance[194]. - The company has implemented a comprehensive information disclosure management system to ensure timely and accurate communication with shareholders[194]. Shareholder Information - The total number of common stock shareholders at the end of the reporting period was 70,694, a decrease from 72,255 at the end of the previous month[151]. - The largest shareholder, Shenzhen Ningrui Investment Management Enterprise (Limited Partnership), holds 93,839,551 shares, representing 7.77% of total shares[151]. - The company does not have a controlling shareholder, as the largest shareholder's stake does not exceed 50%[155]. Future Outlook - The management indicated a positive outlook for the upcoming quarter, projecting a revenue growth of 10%[162]. - The company is exploring potential mergers and acquisitions to enhance its market position[162]. - Future outlook remains positive, with strategic plans in place to enhance operational efficiency and market competitiveness[173].

Financial Performance - Operating revenue increased by 8.88% to CNY 800,885,863.12 for the first nine months compared to the same period last year[6] - Net profit attributable to shareholders increased by 8.39% to CNY 103,786,005.01 for the first nine months compared to the same period last year[6] - Basic earnings per share increased by 8.45% to CNY 0.086[7] - Total revenue for Q3 2018 reached ¥311,870,031.84, an increase of 7.5% compared to ¥290,104,920.29 in Q3 2017[23] - Year-to-date revenue for the first nine months of 2018 was ¥800,885,863.12, up 8.9% from ¥735,547,204.81 in the same period last year[23] - Net profit for Q3 2018 was 30.36 million, compared to 31.85 million in Q3 2017, indicating a decrease of about 4.7%[25] - Operating profit for Q3 2018 was 33.29 million, slightly down from 35.27 million in Q3 2017, a decline of approximately 5.6%[24] - Basic earnings per share for Q3 2018 were 0.0206, compared to 0.0284 in Q3 2017, a decline of about 27.5%[26] - Total comprehensive income for Q3 2018 was -28.66 million, contrasting with 81.49 million in Q3 2017, indicating a significant drop[26] Assets and Liabilities - Total assets decreased by 9.35% to CNY 4,434,657,431.98 compared to the end of the previous year[6] - Net assets attributable to shareholders decreased by 11.79% to CNY 3,335,712,133.51 compared to the end of the previous year[6] - Total assets decreased to ¥4,485,566,796.43 from ¥5,121,204,170.59 at the beginning of the year, representing a decline of 12.4%[21] - Total liabilities decreased to ¥280,972,614.32 from ¥465,702,065.00, a reduction of 39.5%[21] - Owner's equity decreased to ¥4,204,594,182.11 from ¥4,655,502,105.59, reflecting a decrease of 9.7%[21] - Cash and cash equivalents dropped to ¥107,290,365.27 from ¥303,346,402.57, a decline of 64.7%[19] Cash Flow - Net cash flow from operating activities was CNY 24,833,375.14, a significant recovery from a negative cash flow of CNY -20,433,962.78 in the same period last year[6] - Cash flow from operating activities for the first nine months of 2018 was approximately 941 million, slightly up from 927 million in the same period last year[31] - Cash flow from investing activities for Q3 2018 was approximately -189 million, a decline from 31 million in the previous quarter[32] - Cash flow from financing activities for Q3 2018 was approximately -5 million, compared to -28 million in the previous quarter[32] - The cash and cash equivalents at the end of Q3 2018 were approximately 334 million, down from 494 million at the end of the previous quarter[32] - Net cash flow from operating activities turned positive at CNY 22,278,710.23, compared to a negative CNY 9,813,528.07 in the previous year[33] - Cash outflow from investment activities significantly increased to CNY 242,601,829.97, up from CNY 32,455,133.66 year-over-year, indicating a strategic shift towards investment[33] Shareholder Information - The company reported a total of 71,492 shareholders at the end of the reporting period[10] - The top shareholder, Shanghai Songjiang Dongjing Industrial Company, holds 82,082,000 shares, representing 6.80% of total shares[11] Expenses - Sales expenses increased by 72.45% to CNY 72,652,229.16 from CNY 42,129,382.46, driven by higher promotional costs for pharmaceutical products[13] - Employee compensation payable decreased by 60.88% to CNY 20,884,131.67 from CNY 53,380,443.36, due to severance benefits and prior year bonuses being paid[12] - The company paid approximately 171 million in employee compensation during the first nine months of 2018, an increase from 147 million in the same period last year[31] Other Financial Metrics - The company received government subsidies amounting to CNY 367,245.70 during the reporting period[8] - The company reported a total of CNY 551,450.30 in non-recurring gains and losses for the first nine months[8] - Financial assets measured at fair value increased by 723.85% to CNY 99,389,000 from CNY 12,063,899.26 due to the purchase of long-term bonds[12] - Accounts receivable rose by 46.90% to CNY 241,669,268.41 from CNY 164,514,338.90, attributed to increased sales and outstanding payments[12] - Prepayments increased by 48.37% to CNY 23,998,235.16 from CNY 16,174,686.97, driven by higher procurement prepayments[12] - Construction in progress grew by 48.22% to CNY 217,052,896.93 from CNY 146,437,546.37 due to increased investment in new facilities[12] - Accounts payable increased by 53.51% to CNY 124,881,021.02 from CNY 81,348,397.41, reflecting higher unpaid raw material purchases[12] - Customer advances surged by 89.13% to CNY 43,391,261.38 from CNY 22,942,204.31, indicating a rise in prepayments from clients[12] - Other payables increased by 87.99% to CNY 191,548,084.23 from CNY 101,891,925.65, primarily due to temporary receipts and unpaid expenses from pharmaceutical enterprises[12] - Long-term borrowings rose by 71.49% to CNY 55,361,924.68 from CNY 32,283,722.66, attributed to increased bank loans[12]